CoNexus Cancer Care consists of a unique blend of cancer-fighting medicines and immuno-modulating compounds for the treatment of solid tumor cancers.

Each CoNexus Care compound plays a vital role in cancer therapy. CoNexus Care is water-soluble and administered by way of high-pressure injection, placing cancer medicines into the tumor and corresponding tumor cells.

Immuno Modulator Compounds - a newly discovered oxidant hardens the tumor mass by disturbing existing blood vessels within the tumor, ultimately leading to a higher concentration of injected cancer medicines. This hardening of tumor cells effectively changes the extracellular matrix by altering its morphological and biochemical components, e.g., collagen, elastic fibers, reticular fibers, fibronectin, proteoglycans, hyaluronic acid, and other large molecules, eventually "morphing" into a soft, semi-solid state within the tumor.

Another unique feature of CoNexus Care is its ability to avoid administering standard conventional cancer treatment protocols (e.g., Surgery, radiation, and/or chemotherapy) in exchange for a minimally-invasive procedure with no side effects, and to benefit from newer immuno-modulator compounds. When multiple autologous tumor antigens are released from the coagulated tumor, cell death can become a "priming" event for T cell response, which then induces potent immunity within the patient's entire body. These cell deaths are called a "good death", which elicits a weak immune response as an in-vivo self-vaccination promoted by an immunologic modulator, i.e., small molecule haptens. The immuno-modulator reacts within the denatured tumor, causing modified cell debris or matrixes with tumor antigens to produce new and more immunoreactive antigens for better stimulating the host immune system. Therefore, the role of the immuno-modulator is important in enhancing the immunological response to tumor-associated antigens.

• William B. Coley, MD injected live and inactivated Streptococcus pyogenes and Serratia marcescens into patients' tumors in 1891 to try to harness the immune system in the treatment of cancer.
• Lack of a known MOA for 'Coley's toxins' and the risks of infecting cancer patients with pathogenic bacteria caused oncologists to adopt surgery and radiotherapy as standard treatments.
• In the 1970s, large doses of IL-2 were shown to be effective when administered to patients with established, metastatic cancers by enhancing T-cell production.
• The first monoclonal antibody approved by the FDA for the treatment of cancer, non-Hodgkin's lymphoma, came in 1997.
• In 2010, the FDA approved the first cancer vaccine, sipuleucel-T, for castration-resistant prostate cancer.
• In 2011, Ipilimumab, an antibody targeting CTLA-4 was approved by the FDA for use in patients with melanoma.
• In 2014, in Japan nivolumab became the first PD-1 inhibitor to achieve regulatory approval in melanoma.
• Promising results have also been posted for the experimental anti-PD-L1 antibody MPDL3280A in melanoma, lung cancer, and bladder cancer.11,12